1 pending office actions • 0 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
AB Enzymes Finland OY has 1 pending office action currently under review. This prosecution activity involves 1 distinct examiner and 0 distinct art units, indicating a highly specific administrative status for the portfolio. The absence of a recorded art unit suggests a unique or transitional phase in the application's review process. For a practitioner, this singular focus means that the company's immediate patent strategy is entirely dependent on a single point of review within the patent office, with no broader distribution of active matters to balance the portfolio's progress.
ESSEX, LAURA ANN is identified as the busiest examiner, handling 1 busiest examiner pending action. This single action represents the total 1 pending office action for the company, placing the current prosecution focus entirely on this examiner's evaluation. Because the busiest examiner handles the only active action, their feedback and requirements are the sole focus for the company's legal efforts. A successful outcome will require a response strategy that is specifically tailored to this examiner's concerns, as there are no other pending actions to provide alternative opportunities for securing patent protection at this time.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ESSEX, LAURA ANN | 1 | 60.0% | +35.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18578962 | Phytase Variants | ESSEX, LAURA ANN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18578962 | Phytase Variants | ESSEX, LAURA ANN | — |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18578962 | Phytase Variants | ESSEX, LAURA ANN | — | §102§103§112Other | Non-Final OA | — | Pending | Jan 12, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAB Enzymes Finland OY has 1 pending office actions as of October 2026, spread across 0 art units and 1 examiners.
Laura Ann Essex has the most, with 1 of AB Enzymes Finland OY's pending office actions.
